Drug Profile
Research programme: myelosuppression therapy - Hollis-Eden Pharmaceuticals
Alternative Names: HE 3210Latest Information Update: 06 Oct 2008
Price :
$50
*
At a glance
- Originator Hollis-Eden Pharmaceuticals
- Class Androstanes; Chemoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myelosuppression
Most Recent Events
- 11 Oct 2006 Preclinical trials in Myelosuppression in USA (unspecified route)